[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftw3RngxZbzzwGWJMwUYE8zG4YdYWkkth9BqWzYM89lc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"University of Surrey",[4],89,false,11,3,11828,0,74,[14,17,19,22,25,27,29,32],{"name":15,"count":16},"Obesity",7,{"name":18,"count":16},"Healthy",{"name":20,"count":21},"Vitamin D Deficiency",5,{"name":23,"count":24},"Anxiety",4,{"name":26,"count":9},"Stroke",{"name":28,"count":9},"Cancer",{"name":30,"count":31},"Celiac Disease in Children",2,{"name":33,"count":31},"Parents",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,70,96,114,139,165,193,211,229,255,273,291,315,351,369,394,412,436,461,479,497,522,540,564,592,610,628],{"intervention":44,"totalTrials":45,"cells":46},"Vitano",1,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":68},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":67},"NCT01411709","A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress","COMPLETED",[40],"2011-07","2011-01",80,[66],"Mild Stress\u002FAnxiety",[44],{"trials":69,"activeCount":11},[],{"intervention":71,"totalTrials":45,"cells":72},"Insulatard",{"EARLY_PHASE1":73,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":94},{"trials":74,"activeCount":11},[],{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[83],{"nctId":84,"briefTitle":85,"status":60,"phases":86,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":90,"interventions":92},"NCT00788840","Detemir Energy Expenditure Study",[40],"2009-08","2008-01",30,[91,15],"Type 2 Diabetes Mellitus",[71,93],"Detemir",{"trials":95,"activeCount":11},[],{"intervention":93,"totalTrials":45,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":112},{"trials":99,"activeCount":11},[],{"trials":101,"activeCount":11},[],{"trials":103,"activeCount":11},[],{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[108],{"nctId":84,"briefTitle":85,"status":60,"phases":109,"primaryCompletion":87,"completion":87,"start":88,"enrollment":89,"conditions":110,"interventions":111},[40],[91,15],[71,93],{"trials":113,"activeCount":11},[],{"intervention":115,"totalTrials":45,"cells":116},"TicoVac",{"EARLY_PHASE1":117,"PHASE1":119,"PHASE2":121,"PHASE3":123,"PHASE4":125,"NA":137},{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[],{"trials":122,"activeCount":11},[],{"trials":124,"activeCount":11},[],{"trials":126,"activeCount":11},[127],{"nctId":128,"briefTitle":129,"status":60,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT01710189","Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac",[40],"2014-10","2012-10",40,[135],"Tick-Borne Encephalitis",[115],{"trials":138,"activeCount":11},[],{"intervention":140,"totalTrials":45,"cells":141},"rimonabant",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":146,"PHASE3":148,"PHASE4":150,"NA":163},{"trials":143,"activeCount":11},[],{"trials":145,"activeCount":11},[],{"trials":147,"activeCount":11},[],{"trials":149,"activeCount":11},[],{"trials":151,"activeCount":11},[152],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT00584389","The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition","TERMINATED",[40],"2009-04","2010-05","2007-07",14,[15],[140],{"trials":164,"activeCount":11},[],{"intervention":166,"totalTrials":45,"cells":167},"Pregabalin",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":189,"NA":191},{"trials":169,"activeCount":11},[],{"trials":171,"activeCount":11},[],{"trials":173,"activeCount":11},[],{"trials":175,"activeCount":11},[176],{"nctId":177,"briefTitle":178,"status":60,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":183,"interventions":186},"NCT00370656","Effects of Pregabalin, Duloxetine & Amitriptyline on Pain & Sleep",[38,39],"2009-05","2007-02",90,[184,185],"Diabetes Mellitus","Peripheral Neuropathies",[166,187,188],"Duloxetine","Amitriptyline",{"trials":190,"activeCount":11},[],{"trials":192,"activeCount":11},[],{"intervention":187,"totalTrials":45,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":207,"NA":209},{"trials":196,"activeCount":11},[],{"trials":198,"activeCount":11},[],{"trials":200,"activeCount":11},[],{"trials":202,"activeCount":11},[203],{"nctId":177,"briefTitle":178,"status":60,"phases":204,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":205,"interventions":206},[38,39],[184,185],[166,187,188],{"trials":208,"activeCount":11},[],{"trials":210,"activeCount":11},[],{"intervention":188,"totalTrials":45,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":225,"NA":227},{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[],{"trials":218,"activeCount":11},[],{"trials":220,"activeCount":11},[221],{"nctId":177,"briefTitle":178,"status":60,"phases":222,"primaryCompletion":180,"completion":180,"start":181,"enrollment":182,"conditions":223,"interventions":224},[38,39],[184,185],[166,187,188],{"trials":226,"activeCount":11},[],{"trials":228,"activeCount":11},[],{"intervention":230,"totalTrials":45,"cells":231},"Prolonged-release melatonin",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":233,"activeCount":11},[],{"trials":235,"activeCount":11},[236],{"nctId":237,"briefTitle":238,"status":60,"phases":239,"primaryCompletion":87,"completion":87,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT00940550","Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women",[37],"2009-07",16,[243],"Insomnia",[230,245,246],"Temazepam","Zolpidem",{"trials":248,"activeCount":11},[],{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[],{"trials":254,"activeCount":11},[],{"intervention":245,"totalTrials":45,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[261],{"nctId":237,"briefTitle":238,"status":60,"phases":262,"primaryCompletion":87,"completion":87,"start":240,"enrollment":241,"conditions":263,"interventions":264},[37],[243],[230,245,246],{"trials":266,"activeCount":11},[],{"trials":268,"activeCount":11},[],{"trials":270,"activeCount":11},[],{"trials":272,"activeCount":11},[],{"intervention":246,"totalTrials":45,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":289},{"trials":276,"activeCount":11},[],{"trials":278,"activeCount":11},[279],{"nctId":237,"briefTitle":238,"status":60,"phases":280,"primaryCompletion":87,"completion":87,"start":240,"enrollment":241,"conditions":281,"interventions":282},[37],[243],[230,245,246],{"trials":284,"activeCount":11},[],{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[],{"trials":290,"activeCount":11},[],{"intervention":292,"totalTrials":45,"cells":293},"P2G12",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":295,"activeCount":11},[],{"trials":297,"activeCount":11},[298],{"nctId":299,"briefTitle":300,"status":60,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":8,"conditions":304,"interventions":306},"NCT01403792","A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects",[37],"2011-11","2011-06",[305],"Human Immunodeficiency Virus",[292],{"trials":308,"activeCount":11},[],{"trials":310,"activeCount":11},[],{"trials":312,"activeCount":11},[],{"trials":314,"activeCount":11},[],{"intervention":316,"totalTrials":31,"cells":317},"Fluad",{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":319,"activeCount":11},[],{"trials":321,"activeCount":11},[],{"trials":323,"activeCount":11},[],{"trials":325,"activeCount":11},[],{"trials":327,"activeCount":11},[],{"trials":329,"activeCount":11},[330,341],{"nctId":331,"briefTitle":332,"status":60,"phases":333,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":339},"NCT01771367","Training Study to Characterize Biomarkers to Flu Vaccines",[41],"2013-06","2013-11","2013-01",49,[18],[316,340],"Agrippal",{"nctId":342,"briefTitle":343,"status":60,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":349},"NCT02368327","Gene Expression Profiles in Muscle After Immunisation",[41],"2015-07","2015-02",45,[18],[316,350],"Fendrix",{"intervention":340,"totalTrials":45,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":354,"activeCount":11},[],{"trials":356,"activeCount":11},[],{"trials":358,"activeCount":11},[],{"trials":360,"activeCount":11},[],{"trials":362,"activeCount":11},[],{"trials":364,"activeCount":11},[365],{"nctId":331,"briefTitle":332,"status":60,"phases":366,"primaryCompletion":334,"completion":335,"start":336,"enrollment":337,"conditions":367,"interventions":368},[41],[18],[316,340],{"intervention":370,"totalTrials":45,"cells":371},"Varicella-zoster virus",{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[],{"trials":381,"activeCount":11},[],{"trials":383,"activeCount":11},[384],{"nctId":385,"briefTitle":386,"status":60,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":392},"NCT01765413","Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines",[41],"2014-01","2013-09",48,[18],[370,393],"Yellow Fever Vaccine",{"intervention":393,"totalTrials":45,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":397,"activeCount":11},[],{"trials":399,"activeCount":11},[],{"trials":401,"activeCount":11},[],{"trials":403,"activeCount":11},[],{"trials":405,"activeCount":11},[],{"trials":407,"activeCount":11},[408],{"nctId":385,"briefTitle":386,"status":60,"phases":409,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":410,"interventions":411},[41],[18],[370,393],{"intervention":413,"totalTrials":45,"cells":414},"Engerix B Vaccine",{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":416,"activeCount":11},[],{"trials":418,"activeCount":11},[],{"trials":420,"activeCount":11},[],{"trials":422,"activeCount":11},[],{"trials":424,"activeCount":11},[],{"trials":426,"activeCount":11},[427],{"nctId":428,"briefTitle":429,"status":60,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":435},"NCT01771354","Training Study to Characterise Biomarkers to the Engerix B Vaccine",[41],"2014-08","2013-02",24,[18],[413],{"intervention":437,"totalTrials":45,"cells":438},"Engerix B IM injection - 20ug",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[],{"trials":444,"activeCount":11},[],{"trials":446,"activeCount":11},[],{"trials":448,"activeCount":11},[],{"trials":450,"activeCount":11},[451],{"nctId":452,"briefTitle":453,"status":60,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":89,"conditions":457,"interventions":459},"NCT02032160","A Study to Characterise Immune Responses Following Immunisations With \"Fendrix\" or \"Engerix B\" Hepatitis B Vaccines",[41],"2016-02","2014-05",[458],"Hepatitis B",[437,460],"Fendrix IM injection - 20ug",{"intervention":460,"totalTrials":45,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":464,"activeCount":11},[],{"trials":466,"activeCount":11},[],{"trials":468,"activeCount":11},[],{"trials":470,"activeCount":11},[],{"trials":472,"activeCount":11},[],{"trials":474,"activeCount":11},[475],{"nctId":452,"briefTitle":453,"status":60,"phases":476,"primaryCompletion":455,"completion":455,"start":456,"enrollment":89,"conditions":477,"interventions":478},[41],[458],[437,460],{"intervention":350,"totalTrials":45,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":482,"activeCount":11},[],{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[],{"trials":490,"activeCount":11},[],{"trials":492,"activeCount":11},[493],{"nctId":342,"briefTitle":343,"status":60,"phases":494,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":495,"interventions":496},[41],[18],[316,350],{"intervention":498,"totalTrials":45,"cells":499},"Fluenz Tetra",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":501,"activeCount":11},[],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[],{"trials":509,"activeCount":11},[],{"trials":511,"activeCount":11},[512],{"nctId":513,"briefTitle":514,"status":60,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":89,"conditions":518,"interventions":520},"NCT02557802","T-cell Diversity Following Intranasal and Intramuscular Vaccines",[41],"2016-01","2015-10",[519],"Influenza",[498,521],"Fluarix Tetra",{"intervention":521,"totalTrials":45,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":534},{"trials":525,"activeCount":11},[],{"trials":527,"activeCount":11},[],{"trials":529,"activeCount":11},[],{"trials":531,"activeCount":11},[],{"trials":533,"activeCount":11},[],{"trials":535,"activeCount":11},[536],{"nctId":513,"briefTitle":514,"status":60,"phases":537,"primaryCompletion":516,"completion":516,"start":517,"enrollment":89,"conditions":538,"interventions":539},[41],[519],[498,521],{"intervention":541,"totalTrials":45,"cells":542},"Blood draw and finger prick test",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":544,"activeCount":11},[],{"trials":546,"activeCount":11},[],{"trials":548,"activeCount":11},[],{"trials":550,"activeCount":11},[],{"trials":552,"activeCount":11},[],{"trials":554,"activeCount":11},[555],{"nctId":556,"briefTitle":557,"status":60,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":563},"NCT03253055","The D-BIICEP Study",[],"2018-07-01","2018-02-01",50,[20],[541],{"intervention":565,"totalTrials":45,"cells":566},"1% Sodium Tetradecyl Sulphate",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":568,"activeCount":11},[],{"trials":570,"activeCount":11},[],{"trials":572,"activeCount":11},[],{"trials":574,"activeCount":11},[],{"trials":576,"activeCount":11},[],{"trials":578,"activeCount":11},[579],{"nctId":580,"briefTitle":581,"status":60,"phases":582,"primaryCompletion":345,"completion":583,"start":584,"enrollment":585,"conditions":586,"interventions":588},"NCT06192472","Investigation Into the Pathophysiology and Treatment of Varicose Veins",[41],"2015-09","2013-04",120,[587],"Varicose Veins",[565,589,590,591],"3% Sodium Tetradecyl Sulphate","0.5% Polidocanol","3% Polidcanol",{"intervention":589,"totalTrials":45,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":11},[],{"trials":597,"activeCount":11},[],{"trials":599,"activeCount":11},[],{"trials":601,"activeCount":11},[],{"trials":603,"activeCount":11},[],{"trials":605,"activeCount":11},[606],{"nctId":580,"briefTitle":581,"status":60,"phases":607,"primaryCompletion":345,"completion":583,"start":584,"enrollment":585,"conditions":608,"interventions":609},[41],[587],[565,589,590,591],{"intervention":590,"totalTrials":45,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":613,"activeCount":11},[],{"trials":615,"activeCount":11},[],{"trials":617,"activeCount":11},[],{"trials":619,"activeCount":11},[],{"trials":621,"activeCount":11},[],{"trials":623,"activeCount":11},[624],{"nctId":580,"briefTitle":581,"status":60,"phases":625,"primaryCompletion":345,"completion":583,"start":584,"enrollment":585,"conditions":626,"interventions":627},[41],[587],[565,589,590,591],{"intervention":591,"totalTrials":45,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":11},[],{"trials":633,"activeCount":11},[],{"trials":635,"activeCount":11},[],{"trials":637,"activeCount":11},[],{"trials":639,"activeCount":11},[],{"trials":641,"activeCount":11},[642],{"nctId":580,"briefTitle":581,"status":60,"phases":643,"primaryCompletion":345,"completion":583,"start":584,"enrollment":585,"conditions":644,"interventions":645},[41],[587],[565,589,590,591]]